Prostate Cancer

Prostate cancer is the second most common form of cancer in men.  Approximately 910,000 cases of prostate cancer were recorded in 2008, accounting for nearly 14% of all new cancer cases in men. It is predicted that the number of cases will almost double to 1.7 million by 2030.


The FASTPATH program aims to make a significant difference in our understanding and treatment of this form of cancer.

A consortium of industrial and academic partners, it was successfully awarded a European Marie Curie FP7 grant in November 2011.  The grant was awarded with the purpose of developing high-throughput image analysis solutions for prostate cancer. The industrial partners, OncoMark Ltd. and PathXL, are developing and validating novel prostate biomarker imaging algorithms, tumour identification, quantitative IHC and image search techniques and subsequently bringing these to the market.

Marie Curie Industry Academia Partnerships and Pathways

The FAST-PATH project is a Marie Curie 'Industry-Academic Pathways and Partnerships' (IAPP) programe which aims to stimulate intersectoral mobility and increase knowledge sharing through joint research partnerships in longer term co-operation programmes between organisations from academia and industry, in particular SMEs and including traditional manufacturing industries.